PT - JOURNAL ARTICLE AU - Niyomnaitham, Suvimol AU - Chatsiricharoenkul, Somruedee AU - Toh, Zheng Quan AU - Senawong, Sansnee AU - Pheerapanyawaranun, Chatkamol AU - Phumiamorn, Supaporn AU - Licciardi, Paul V AU - Chokephaibulkit, Kulkanya TI - Evaluation of the safety and immunogenicity of fractional intradermal COVID-19 vaccines as a booster: A pilot study AID - 10.1101/2022.07.27.22278116 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.27.22278116 4099 - http://medrxiv.org/content/early/2022/07/29/2022.07.27.22278116.short 4100 - http://medrxiv.org/content/early/2022/07/29/2022.07.27.22278116.full AB - Intradermal vaccination using fractional dosage of the standard vaccine dose is one strategy to improve access to COVID-19 immunization. We conducted a pilot study in healthy adults in Thailand to evaluate the safety and immunogenicity of intradermal administration of fractional dose of ChAdOx1 (1/5th of standard dosage) or BNT162b2 (1/6th of standard dosage) to individuals previously vaccinated (prime) with two-dose intramuscular CoronaVac, ChAdOx1 or BNT162b2. Following an initial immunogenicity exploratory phase for each vaccine combination group (N=10), a total of 135 participants (N=45 per group) were recruited to three groups (CoronaVac prime-intradermal BNT162b2 boost, CoronaVac prime-intradermal ChAdOx1 boost and ChAdOx1 prime-intradermal BNT162b2 boost) and their immunogenicity data compared to a previous cohort who received the same vaccine intramuscularly. Two weeks following booster vaccination, neutralizing antibodies against the delta variant were similar between intradermal and intramuscular vaccination. However, neutralizing antibodies against the omicron variant in the intradermal BNT162b2 boost groups were ∼6-fold lower, while the ChAdOx1 boost group was ∼5-fold higher compared to their respective vaccine regimen given intramuscularly. The intradermal booster significantly increased spike-specific T cell responses in all three groups from pre-booster levels. Local and systemic adverse reactions were milder in intradermal compared to intramuscular injections. Further studies are needed to evaluate the clinical relevance of these findings and the feasibility of administration of intradermal COVID-19 vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210907003 and TCTR20211102006Funding StatementThis study was supported by Health Systems Research Institute, Thailand. (Grant number 64-209 and 65-009)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards of the Committee on Ethics, Faculty of Medicine Siriraj Hospital, Mahidol University. Certificate of approval number Si635/2021 and Si894/2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study are available on request from the corresponding author.